Objectives: To evaluate the in vitro activity of ceftazidime/avibactam relative to comparator agents against Gram-negative isolates from a Phase 3 clinical trial programme for complicated urinary tract infections (RECAPTURE).
Introduction
Since the approval of ceftazidime, a variety of new ESBLs have been identified and become more prevalent, which has eroded the effectiveness of cephalosporins, including ceftazidime. 1 Avibactam is a non-b-lactam b-lactamase inhibitor with a broader spectrum inhibitory activity against Ambler class A and C b-lactamases and some Ambler class D enzymes than previous generations of inhibitors including enzymes such as KPC and OXA-48. 2, 3 The combination of ceftazidime and avibactam has a spectrum of activity that includes ESBL-producing, as well as KPC-and OXA-48-producing, Enterobacteriaceae and Pseudomonas aeruginosa with derepressed AmpC. 2, [4] [5] [6] Ceftazidime/avibactam is a new antibacterial agent that has been recently approved in the USA for treating serious infections due to Gram-negative bacteria. 7 Two double-blind, double-dummy, pivotal Phase 3 studies, which were subsequently analysed as a final single study (RECAPTURE), were conducted to assess the safety and efficacy of ceftazidime/avibactam compared with the active comparator doripenem, in complicated urinary tract infections (cUTIs) due to Gram-negative organisms. 8 Bacterial cultures were isolated from patient specimens and submitted to a central laboratory for identification and susceptibility testing. This report summarizes the in vitro susceptibility of these clinical isolates to ceftazidime/avibactam and relevant comparative agents.
Methods
Double-blind clinical trials (RECAPTURE 1 and 2) comparing the safety and efficacy of ceftazidime/avibactam versus doripenem in cUTIs were conducted from October 2012 to August 2014. 8 Specimens in this study obtained from all randomized patients were processed at the institution's (or regional) laboratory according to local practices. All Gram-negative V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com. bacterial pathogens were sent to a central laboratory (Covance Central Laboratory Services, Indianapolis, IN, USA) for identification and susceptibility testing. Susceptibility testing was performed and interpreted according to CLSI methodologies. 9, 10 Interpretive criteria set by the US FDA were used for tigecycline and ceftazidime/avibactam. 11, 12 For ceftazidime/avibactam susceptibility testing, avibactam was tested at a constant concentration of 4 mg/L in doubling dilutions of ceftazidime. All agents were tested by reference broth microdilution methods using frozen panels according to manufacturer's recommendations (TREK Diagnostics, Westlake, OH, USA). Phenotypic detection of ESBL enzyme production was performed according to CLSI guidelines 9 using the screening and confirmatory tests. Reference antibiotics included the comparator doripenem and representative agents in relevant classes for comparative purposes. Genetic identification of b-lactamases and upregulation of AmpC was provided by JMI Laboratories, Inc. (North Liberty, IA, USA), as described previously. 13 Only baseline pathogens from all randomized patients were included in the analysis of susceptibility testing to ceftazidime/avibactam and comparators. If more than one isolate of the same species was isolated at baseline and tested, the strain with the highest MIC of study drug received was used for the analysis.
Results and discussion
A total of 840 baseline pathogens (of which 799 isolates were Enterobacteriaceae and 41 isolates were P. aeruginosa) were identified from the urine samples of the 1033 randomized patients in the RECAPTURE programme. Of the 1033 patients, 207 did not have a Gram-negative pathogen that was .10 5 cfu/mL at baseline and isolates were not submitted to the central laboratory. Table S1 (available as Supplementary data at JAC Online) summarizes the number of patients with each species within each treatment arm for the most prevalent organisms. The distribution of Gram-negative pathogens isolated from urine specimens was typical of that observed in previous clinical trials. 14 Among the Enterobacteriaceae, Escherichia coli (58.3% of patients) was the most common organism isolated, followed by Klebsiella pneumoniae (10.4%), Proteus mirabilis (3.4%) and Enterobacter cloacae (2.4%).
The susceptibility to ceftazidime/avibactam and comparator agents is shown in Table 1 and Table S2 . There was a significant reduction in the ceftazidime/avibactam MIC relative to ceftazidime alone in most of the Enterobacteriaceae isolates, similar to what has previously been observed in non-clinical in vitro studies and surveillance. [15] [16] [17] Ceftazidime/avibactam was very active against all Enterobacteriaceae, with an overall MIC 50 and MIC 90 of 0.06 and 0.5 mg/L, respectively. Against the most common pathogens, the ceftazidime/avibactam MIC 90 values were 0.25 mg/L for E. coli, 1 mg/L for K. pneumoniae, 0.06 mg/L for P. mirabilis and 2 mg/L for E. cloacae. The MIC values of ceftazidime/avibactam were similar to those observed for the tested carbapenems (imipenem and doripenem) and tigecycline.
Against 154 ceftazidime-non-susceptible isolates of Enterobacteriaceae, the overall ceftazidime/avibactam MIC 90 was 1 mg/L. Against the most common ceftazidime-non-susceptible pathogens (E. coli, K. pneumoniae and E. cloacae), the ceftazidime/ avibactam MIC 90 values were 0.5, 2 and 4 mg/L, respectively (Table S3 ). The MIC frequency distribution for ceftazidime/avibactam and ceftazidime against the ceftazidime-non-susceptible isolates of Enterobacteriaceae (ceftazidime MIC 8 mg/L) is displayed in Figure 1 . The majority of isolates tested at 4 mg/L for ceftazidime/avibactam. There were two isolates that tested .4 mg/L; one Providencia rettgeri (ceftazidime/avibactam MIC 32 mg/L) and one K. pneumoniae (MIC .64 mg/L). It has been shown previously that the K. pneumoniae produced an NDM-1 metallo-b-lactamase. This can explain the high ceftazidime/avibactam MIC, as avibactam has no inhibitory effect on class B metallo-b-lactamases. 18, 19 However, the P. rettgeri isolate was phenotypically positive for the hyper-expression of AmpC, but was not positive for one of the acquired screened b-lactamases. 13 It could be that an unidentified b-lactamase is present in this organism due to limitations of the identification system or other unexplored mechanisms such as efflux. In addition, it has previously been shown that mutations in ampC were associated with reduced susceptibility to ceftazidime/avibactam 20 as well as mutations in PBP3; 21 however, these mutations were not explored in this isolate.
Against 41 isolates of P. aeruginosa, the MIC 90 was 8 mg/L, which was one dilution more active than the carbapenems, doripenem and imipenem, which were both 16 mg/L. The ceftazidime/ N, all randomized patients; n, number of pathogens tested. See Table S2 for all comparative agents used within the study.
Ceftazidime/avibactam versus urinary isolates JAC avibactam MIC 90 for 15 ceftazidime-non-susceptible isolates of P. aeruginosa was 64 mg/L (Table S3 ). The ceftazidime/avibactam MIC 50 was reduced three dilutions in relation to ceftazidime, from 32 to 4 mg/L; however, the MIC 90 was not reduced in relation to ceftazidime, which is due to the fact that four of the isolates contained either a class D carbapenemase (OXA-2; two isolates) or a class B carbapenemase (one isolate each of VIM-2 and IMP-18) against which avibactam has no inhibitory activity. 22 The ceftazidime/avibactam MICs for these four isolates were not reduced in comparison with ceftazidime alone. The activity of ceftazidime/ avibactam against the P. aeruginosa isolates that did not contain the class D or B carbapenemase enzymes was in agreement with several pre-clinical studies demonstrating that there is usually a 3-4 dilution decrease in MIC values when avibactam is added to ceftazidime in susceptibility testing. 10, 23 There were 135 of 751 isolates of Enterobacteriaceae (85 E. coli, 48 K. pneumoniae and 2 P. mirabilis) that were phenotypically positive for an ESBL (Table S4 ). The ceftazidime/avibactam MIC 90 values for ESBL phenotype-positive isolates of E. coli and K. pneumoniae were 0.5 and 2 mg/L, respectively, whereas the ceftazidime/avibactam MIC 90 values for the ESBL phenotype-negative isolates of E. coli and K. pneumoniae were slightly lower (0.12 and 0.5 mg/L, respectively).
Twenty-one baseline bacterial isolates were AmpC hyperproducers, either as the sole mechanism of resistance identified (11 strains) or in combination with other enzymes (10 strains). The majority of the isolates were E. cloacae (11 strains), followed by P. aeruginosa (6 strains), Citrobacter freundii (3 strains) and Enterobacter aerogenes (1 strain). For 14 of the 15 Enterobacteriaceae, the MICs were reduced from 32 mg/L for ceftazidime to 4 mg/L for ceftazidime/avibactam. Five of the six isolates of P. aeruginosa were hyperproducers of AmpC as the only b-lactamase present and one strain was a hyperproducer in combination with an OXA-2. There was a 2-4-fold reduction in MICs of ceftazidime/avibactam in relation to ceftazidime for the five strains of AmpC hyperproducers as the only b-lactamase present. The MIC range of ceftazidime/avibactam for these strains was 4-16 mg/L.
In conclusion, ceftazidime/avibactam was highly active in vitro against Gram-negative isolates from the RECAPTURE Phase 3 clinical programme for the treatment of cUTIs. This included isolates that were not susceptible to ceftazidime due to ESBL and/or upregulated AmpC production. Ceftazidime/avibactam was shown to be efficacious and well tolerated in the global trial programme, including patients with isolates nonsusceptible to ceftazidime, 8 suggesting the utility of ceftazidime/avibactam in treating patients with cUTIs caused by Gram-negative pathogens.
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